Summary & Overview
HCPCS J9044: Injection, bortezomib, 0.1 mg
HCPCS Level II code J9044 denotes a 0.1 mg unit of injectable bortezomib, an antineoplastic agent widely used in oncology care. This billing code captures drug supply units for chemotherapy administration and is central to outpatient and facility chemotherapy billing. Accurate use of J9044 affects drug utilization reporting, patient cost-sharing, and facility reimbursement for oncology services across settings.
Key payers covered in national analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for bortezomib administration, typical sites of service where J9044 is billed, and what to expect in payer coverage patterns. The publication summarizes common modifiers and administrative considerations relevant to HCPCS drug coding (listed separately), benchmarks for unit reporting, and implications for claims processing workflows.
The article provides practical billing context rather than clinical guidance: how J9044 maps to service lines, typical encounter settings, and the operational points that influence reimbursement and reporting for this injectable chemotherapy drug. Data not provided in the input are identified explicitly.
Billing Code Overview
HCPCS Level II code J9044 represents an injection of bortezomib, not otherwise specified, 0.1 mg. This code describes the billed supply or drug administration unit for the chemotherapy agent bortezomib delivered as an injectable preparation.
-
Service type: Drug administration (injectable antineoplastic agent)
-
Typical site of service: Infusion center, hospital outpatient department, physician office
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J9044 (injection, bortezomib, not otherwise specified, 0.1 mg) is an adult with a diagnosis such as multiple myeloma or mantle cell lymphoma presenting for outpatient or hospital-based oncology infusion. The clinical workflow begins with oncology evaluation and chemotherapy order entry by a board-certified medical oncologist or hematologist, including dosing calculation based on body surface area or fixed dosing per protocol, review of prior cycles and laboratory values (complete blood count, platelet count, hepatic function), and assessment for peripheral neuropathy or other contraindications. A certified oncology nurse performs pre-infusion verification, obtains informed consent, performs baseline vital signs, and establishes appropriate vascular access (peripheral IV or implanted venous access device). Bortezomib is prepared by pharmacy under sterile compounding conditions, labeled as J9044 units per 0.1 mg, and delivered to the infusion area. The medication is administered subcutaneously or intravenously per regimen; nursing documents dose, route, lot number, and patient tolerance. Post-administration monitoring includes observation for acute reactions, antiemetic or supportive medication administration, and scheduling of follow-up labs and subsequent cycles. Billing uses J9044 by 0.1 mg units, with appropriate administration CPT codes and applicable modifiers reported according to payer rules.
Coding Specifications
| Modifier | Description | When to Use |
|---|